Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma
NCT06239727Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2024
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Sun Yat-sen University. Primary endpoint: Locoregional failure-free survival at 3 years. Started Mar 2024; status: recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06239727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239727.